Comparative study of radiologists vs machine learning in differentiating biopsy-proven pseudoprogression and true progression in diffuse gliomas - 14/07/22

Doi : 10.1016/j.neuri.2022.100088 
Sevcan Turk a, c, , 1 , Nicholas C. Wang b, Omer Kitis c, Shariq Mohammed b, d, Tianwen Ma d, Remy Lobo a, John Kim a, Sandra Camelo-Piragua e, Timothy D. Johnson d, Michelle M. Kim g, Larry Junck f, Toshio Moritani a, Ashok Srinivasan a, Arvind Rao b, Jayapalli R. Bapuraj a
a Department of Radiology, Division of Neuroradiology Michigan Medicine Ann Arbor Michigan, United States of America 
b Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, United States of America 
c Department of Radiology, Ege University Izmir, Turkey 
d Department of Biostatistics, University of Michigan, Ann Arbor Michigan, United States of America 
e Department of Pathology, Division of Neuropathology, University of Michigan, Ann Arbor Michigan, United States of America 
f Department of Neurology, University of Michigan Ann Arbor Michigan, United States of America 
g Department of Radiation Oncology, University of Michigan Ann Arbor Michigan, United States of America 

Corresponding author at: 1500E. Medical Center Drive, University Hospital, B2A209B SPC5030, Ann Arbor MI 48109-5030, USA.1500EMedical Center DriveUniversity HospitalB2A209B SPC5030Ann ArborMI48109-5030USA

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Background and Purpose

MRI features of tumor progression and pseudoprogression may be indistinguishable especially without enhancing portion of the diffuse gliomas. Our aim is to discriminate these two conditions using radiomics and machine learning algorithm and to compare them with human observations.

Materials and Methods

Three consecutive MRI studies before a definitive biopsy in 43 diffuse glioma patients (7 pseudoprogression and 36 true progression cases) who underwent treatment were evaluated. Two neuroradiologists reviewed pre- and post-contrast T1, T2, FLAIR, ADC, rCBV, rCBF, K2, and MTT maps. Patterns of enhancement, ADC maps, rCBV, rCBF, MTT, K2 values, and perilesional FLAIR signal intensity changes were recorded. Odds ratios (OR) for each descriptor, raters' success in predicting true and pseudoprogression, and inter-observer reliability were calculated using the R statistics software. Unpaired Student's t-test and receiver operating characteristic (ROC) analysis were applied to compare the texture parameters and histogram analysis of pseudo- and true progression groups. All first-order and second-order image texture features and shape features were used to train and test the Random Forest classifier (RFC). Observers' success and RFC were compared.

Results

Observers could not identify true progression in the first visit. However, accuracy of the RFC model was 81%. For the second and third visits, the rater's success of prediction was between 62% and 72%. The accuracy for the second and last visit with RFC was 75% and 81%.

Conclusions

Random Forest classifier was more successful than human observations in predicting pseudoprogression using MRI.

El texto completo de este artículo está disponible en PDF.

Keywords : Pseudoprogression, Tumor progression, Machine learning, Radiomics, Glial tumor


Esquema


© 2022  The Author(s). Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 2 - N° 3

Artículo 100088- septembre 2022 Regresar al número
Artículo precedente Artículo precedente
  • Efficacy of melatonin for febrile seizure prevention: A clinical trial study
  • Siriluk Assawabumrungkul, Vibudhkittiya Chittathanasesh, Thitiporn Fangsaad
| Artículo siguiente Artículo siguiente
  • NOWinBRAIN 3D neuroimage repository: Exploring the human brain via systematic and stereotactic dissections
  • Wieslaw L. Nowinski

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.